A novel dosing strategy of ceftolozane/tazobactam in a patient receiving intermittent hemodialysis
Abstract We describe a case of a 54 years old male receiving intermittent hemodialysis (iHD) who was found to have P. aeruginosa bacteremia secondary to osteomyelitis of the calcaneus bone. The patient was clinically cured without recurrence using a ceftolozane/tazobactam (CTZ) dosing strategy of 100/50mg every 8 hours (standard dosing) and 1000/500mg thrice weekly following iHD. Utilizing a susceptibility breakpoint of ≤ 4 µg/ml for P. aeruginosa, the T>MIC for standard dosing and the 1000/500mg thrice weekly following iHD regimen were calculated to be 92.7% and 94.1%, respectively. Ceftolozane total body clearance for the standard q 8 h dosing and the 1000/500mg thrice weekly following iHD regimen were calculated to be 0.196 L/h and 0.199 L/h, respectively. To our knowledge, this is the first report to illustrate the administration of CTZ at a dose of 1000/500mg thrice weekly following iHD.